Background Image
Menu

News: 2021

Cytox launches genoSCORE-LAB test to predict the risk of developing Alzheimer’s disease

24 February 2021

Cytox launches genoSCORE-LAB test to predict the risk of developing Alzheimer’s disease

Non-invasive genetic test enables physicians to assess an individual’s risk of cognitive decline due to Alzheimer’s from a simple saliva sample provided from home … Test can guide lifestyle interventions to potentially slow disease progression … 24th February 2021:

The pill could be sold in pharmacies without prescription

16 February 2021

The pill could be sold in pharmacies without prescription

Some contraceptive pills could be sold over the counter in the UK for the first time, the government has said. It is asking the public for their views on whether two progestogen-only pills, also known as the "mini-pill", should be available without prescription. The move has...

Maxwellia announces appointment of Tim Holmes as Head of Sales

11 February 2021

Maxwellia announces appointment of Tim Holmes as Head of Sales

Maxwellia, the UK’s only dedicated expert medicines switching company, has appointed Tim Holmes to the newly created role of Head of Sales with responsibility for building the company’s customer strategy and customer success model. The appointment is the second so...

Maxwellia spearheading shift to self-care with three pharmacy products in launch pipeline

11 February 2021

Maxwellia spearheading shift to self-care with three pharmacy products in launch pipeline

Push to convert more prescription medicines to over-the-counter will put pharmacists at heart of nation's public health, helping futureproof NHS … LONDON, Feb. 11, 2021 - Pioneering pharma company Maxwellia is poised to transform the UK's self-care market by giving people easier...

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence

2 February 2021

AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence

Liege, Februray, 02, 2021 – Belgium-based AARDEX Group, the world leader in medication adherence solutions, today announced a strategic partnership with Pill Connect Ltd, an English company specializing in the design, development and manufacture of innovative medical...

Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate

1 February 2021

Blueberry Therapeutics announces extension of its Series B round with investment from Medical Incubator Japan and US Dermatology Syndicate

Blueberry Therapeutics Limited would like to announce that it has completed a £3.6m extension to the previously successful Series B Fundraising of £10.8m. This investment is from a Japanese investor, Medical Incubator Japan (MIJ) and a private syndicate of US Board...

Chris Hall elected chairman of Pill Connect

28 January 2021

Chris Hall elected chairman of Pill Connect

MANCHESTER, U.K. — Pill Connect, formerly known as Elucid mHealth, has elected Chris Hall chairman of the company. Pill Connect is a world leader in medicine adherence monitoring and data capture on patient compliance. This follows the recent successful funding raise...

Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites

27 January 2021

Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites

Panthera continues to sign up new contracts despite COVID -19. Unlike many other clinical trial sites, Panthera’s dedicated sites do not mix clinical trial patients with other patients minimizing the risk of COVID -19 infection for both patients and staff. Many research...

Manchester Imaging teams up with Michelson Diagnostics

21 January 2021

Manchester Imaging teams up with Michelson Diagnostics

Michelson Diagnostics Ltd, manufacturer of the world-leading VivoSight™ OCT skin imaging and measurement system, has teamed up with AI specialists Manchester Imaging Ltd, to aid dermatologists in the fight against skin cancer and other skin diseases. Michelson’s...

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

20 January 2021

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics Ltd. (“OBT”), a...